Galectin Therapeutics Inc. (GALT)

NASDAQ: GALT · IEX Real-Time Price · USD
1.80
-0.02 (-1.10%)
Jan 28, 2022 2:51 PM EST - Market open
Market Cap106.81M
Revenue (ttm)n/a
Net Income (ttm)-31.33M
Shares Out59.34M
EPS (ttm)-0.54
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume109,253
Open1.80
Previous Close1.82
Day's Range1.80 - 1.87
52-Week Range1.71 - 5.70
Beta1.93
AnalystsBuy
Price Target14.00 (+677.8%)
Earnings Daten/a

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which i...

IndustryBiotechnology
Founded2000
CEOHarold Shlevin
Employees6
Stock ExchangeNASDAQ
Ticker SymbolGALT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for GALT stock is "Buy" and the 12-month stock price forecast is 14.00.

Price Target
$14.00
(677.78% upside)
Analyst Consensus: Buy

News

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be parti...

3 weeks ago - GlobeNewsWire

Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein

NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the ...

1 month ago - GlobeNewsWire

Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potent...

NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022

1 month ago - GlobeNewsWire

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update

Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program

2 months ago - GlobeNewsWire

UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

NORCROSS, Ga., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will present six s...

2 months ago - GlobeNewsWire

Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

NORCROSS, Ga., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will present six s...

3 months ago - GlobeNewsWire

UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12...

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be parti...

3 months ago - GlobeNewsWire

Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company's management ...

3 months ago - GlobeNewsWire

Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company's management...

4 months ago - GlobeNewsWire

Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy an...

NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has recen...

4 months ago - GlobeNewsWire

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update

Considering options for a Combination Cancer Immunotherapy trial based on encouraging results of Phase 1b trial which strengthened the rationale to conduct a larger, randomized controlled Phase 2 study ...

5 months ago - GlobeNewsWire

GALT Stock: The Big Trial News That Has Galectin Therapeutics Soaring

Today, a key announcement of some positive clinical trial data has sent investors in Galectin and GALT stock on a nice ride. The post GALT Stock: The Big Trial News That Has Galectin Therapeutics Soarin...

6 months ago - InvestorPlace

Why Galectin Is Soaring And Sigilon Is Sinking Today

Galectin Therapeutics Inc. (NASDAQ: GALT) and Sigilon Therapeutics, Inc. (NASDAQ: SGTX) are among the biggest movers among biopharma stocks in early trading Friday. Galectin Spikes On Positive Data For ...

Other symbols:SGTX
6 months ago - Benzinga

Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer

Galectin Therapeutics Inc (NASDAQ: GALT) has announced top-line clinical data from the extension cohort of Phase 1b trial of Belapectin in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrol...

6 months ago - Benzinga

8 ‘Must Watch' Penny Stocks For Your July 2021 List

Are these 'must watch' penny stocks on your radar? The post 8 ‘Must Watch' Penny Stocks For Your July 2021 List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

6 months ago - PennyStocks

Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in C...

NORCROSS, Ga., July 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and the Earle A. Chiles Research Institute...

6 months ago - GlobeNewsWire

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update

Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials

8 months ago - GlobeNewsWire

Galectin Therapeutics to Present at 4th Global NASH Congress

NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D.,...

9 months ago - GlobeNewsWire

Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response

Galectin Therapeutics Inc (NASDAQ: GALT) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's bel...

9 months ago - Benzinga

Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics' Ga...

Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone Combination therapy with belapectin suggests a better objecti...

9 months ago - GlobeNewsWire

Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NAS...

Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis Galectin Therapeutic...

9 months ago - GlobeNewsWire

Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and pro...

9 months ago - GlobeNewsWire

Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020

NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., ...

1 year ago - GlobeNewsWire

Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation

Chairman Dick Uihlein, CEO and President Joel Lewis, and Chief Medical Officer Pol Boudes Provide Corporate Highlights on Company's Three Active Clinical Trials Chairman Dick Uihlein, CEO and President ...

1 year ago - GlobeNewsWire

Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020

Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated

1 year ago - GlobeNewsWire